Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Celularity Inc (CELUW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/12/2025: CELUW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/12/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 5038 | Beta 0.76 | 52 Weeks Range 0.01 - 0.12 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.12 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.77% | Operating Margin (TTM) -52.25% |
Management Effectiveness
Return on Assets (TTM) -17.42% | Return on Equity (TTM) -232.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11684589 |
Shares Outstanding - | Shares Floating 11684589 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Celularity Inc
Company Overview
History and Background
Celularity Inc. was formed in 2017 and went public via SPAC merger in 2021. It focuses on developing and commercializing allogeneic cellular therapies derived from the postpartum human placenta.
Core Business Areas
- Allogeneic Cell Therapy: Development of off-the-shelf cell therapies using cells derived from the placenta to treat various diseases including hematological malignancies, solid tumors, and autoimmune diseases. Key product candidates include CYNK-001, CYNK-101 and PDA-002
- Biorepository: Cryopreservation and storage of placental-derived cells for potential future therapeutic use.
Leadership and Structure
Robert J. Hariri, M.D., Ph.D. is the Founder, Chairman and Chief Executive Officer. The company operates with a structure typical of a biotechnology firm, focused on research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- CYNK-001: An off-the-shelf natural killer (NK) cell therapy being evaluated in clinical trials for hematologic malignancies such as multiple myeloma and acute myeloid leukemia (AML). Market share is currently nascent, focusing on clinical trial outcomes. Competitors include Fate Therapeutics (FATE) and Nkarta (NKTX).
- PDA-002: Placental-derived mesenchymal-like adherent stromal cell (MLASC) therapy being evaluated for the treatment of Crohn's disease. Market share is currently limited to clinical trials. Competitors include Mesoblast (MESO) and Takeda (TAK).
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advances in biotechnology and increasing demand for novel therapies to treat unmet medical needs. It is a high-risk, high-reward sector with significant regulatory hurdles and development costs.
Positioning
Celularity is positioned as a player in the allogeneic cell therapy space, focusing on placental-derived cells. Their competitive advantage lies in the potential scalability and cost-effectiveness of sourcing cells from the placenta.
Total Addressable Market (TAM)
The cell therapy market is projected to reach hundreds of billions of dollars in the coming years. Celularity is focused on capturing a portion of this TAM by targeting specific disease indications with its cell therapy candidates.
Upturn SWOT Analysis
Strengths
- Proprietary placental-derived cell therapy platform
- Strong intellectual property portfolio
- Experienced leadership team
- Potential for off-the-shelf allogeneic therapies
- Established biorepository
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Relatively early stage of development
- High risk of clinical trial failure
- Need for regulatory approval
Opportunities
- Expansion into new disease indications
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Advancements in cell therapy technology
- Growing demand for cell therapies
Threats
- Competition from other cell therapy companies
- Regulatory hurdles and delays
- Clinical trial failures
- Manufacturing challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- FATE
- MESO
- NKTX
- CRIS
- BMY
Competitive Landscape
Celularity faces intense competition in the cell therapy space. While its placental-derived cell therapy platform offers potential advantages, it must demonstrate superior efficacy and safety compared to competing therapies to gain market share.
Major Acquisitions
Legacy Celularity
- Year: 2019
- Acquisition Price (USD millions): 250
- Strategic Rationale: Celularity acquired the legacy Celularity assets to consolidate its cell therapy platform and intellectual property.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited to progress within clinical trials and partnership establishment.
Future Projections: Future growth is contingent on clinical trial success and regulatory approvals for its cell therapy candidates. Analyst estimates are highly variable.
Recent Initiatives: Recent initiatives include advancing clinical trials for CYNK-001 and PDA-002, and establishing strategic partnerships.
Summary
Celularity is a high-risk, high-reward clinical-stage biotech company developing placental-derived cell therapies. Positive clinical trial results and regulatory approvals are crucial for its success. The company faces strong competition and requires significant funding to advance its pipeline. The current market share is low with most focus around clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Celularity Inc. website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celularity Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-07-19 | Founder, CEO & Chairman Dr. Robert Joseph Hariri M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.celularity.com |
Full time employees 123 | Website https://www.celularity.com | ||
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.